A65-year-old man was admitted to our hospital with a 6-month history of increasing
abdominal size. His medical history was unremarkable. On physical examination, a mass …

Dear Editor, Imatinib is an accepted therapeutic option for gastrointestinal stromal tumors
(GIST). Imatinib is metabolized by CYP3A4, which is the predominant cytochrome P450 …

A 52-year-old woman with metastatic gastro-intestinal stromaceltumor (GIST) presented
herself in March 2006 with tumor-related intra-abdominal obstructions and diffuse intra …

Imatinib mesylate is a drug that has been approved for treatment of chronic myeloid
leukemia, Philadelphia-positive acute lymphoblastic leukemia, and advanced …

Imatinib mesylate is used for the treatment of patients with Philadelphia chromosome–
positive chronic myeloid leukemia and gastrointestinal stromal tumors (GISTs). It has been …

We report the first case of hepatocellular injury occurring in a patient treated for metastatic
gastrointestinal stromal tumour (GIST) with imatinib mesylate, with two positive rechallenges …

We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after
previous failed extensive therapy, including multiple surgeries and hepatic artery …

Background Imatinib mesylate has been used for the treatment of unresectable or metastatic
gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 …

Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic
myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a …

A 49-year-old man presented with rapidly growing, nontender sternal and forehead masses.
An incisional biopsy showed plasmacytoma with amyloid deposits around blood vessels …